Mixed-effects modelling to quantify the effect of empagliflozin on renal glucose reabsorption in patients with type 2 diabetes
Author:
Affiliation:
1. Metrum Research Group; Tariffville CT USA
2. Nippon Boehringer Ingelheim Co. Ltd; Hyogo Japan
3. Boehringer Ingelheim Pharma GmbH & Co. KG; Ingelheim Germany
4. Boehringer Ingelheim Pharma GmbH & Co. KG; Biberach Germany
Funder
Boehringer Ingelheim
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12597/fullpdf
Reference29 articles.
1. International Diabetes Federation. Diabetes Atlas Sixth Edition 2013 http://www.idf.org/sites/default/files/EN_6E_Atlas_Exec_Sum_1.pdf
2. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors;Grempler;Diabetes Obes Metab,2012
3. SGLT2 mediates glucose reabsorption in the early proximal tubule;Vallon;J Am Soc Nephrol,2011
4. Improved glycemic control in mice lacking Sglt1 and Sglt2;Powell;Am J Physiol Endocrinol Metab,2013
5. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus;Nair;J Clin Endocrinol Metabol,2010
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study;Journal of Diabetes Investigation;2021-02-05
2. Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods;European Journal of Pharmaceutical Sciences;2020-04
3. Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study;BMJ Open;2020-02
4. Favourable effect of the sodium‐glucose co‐transporter‐2 inhibitor canagliflozin plus the dipeptidyl peptidase‐4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open‐label, prospective, randomized, parallel‐group comparison trial (the CALMER study);Diabetes, Obesity and Metabolism;2019-10-13
5. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes—cardiovascular and renal benefits in patients with chronic kidney disease;European Journal of Clinical Pharmacology;2019-08-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3